Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

Abstract Background Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and the most common systemic disorder associated with uveitis in childhood. Uveitis is more common in JIA patients who are antinuclear antibody (ANA)-positive, have an early-onset disease, and have...

Full description

Bibliographic Details
Main Authors: Athimalaipet V. Ramanan, Catherine M. Guly, Stuart Y. Keller, Douglas E. Schlichting, Stephanie de Bono, Ran Liao, Pierre Quartier
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Trials
Subjects:
Antinuclear antibody-positive
Baricitinib
Bayesian analysis
Juvenile idiopathic arthritis
Open-label Bayesian design
Ophthalmology
Online Access:https://doi.org/10.1186/s13063-021-05651-5

Internet

https://doi.org/10.1186/s13063-021-05651-5

Similar Items